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The prevalence of penicillin-nonsusceptible pneumococci is sharply divided between France (43%) and
Germany (7%). These differences may be explained on different levels: antibiotic-prescribing practices for
respiratory tract infections; patient-demand factors and health-belief differences; social determinants,
including differing child-care practices; and differences in regulatory practices. Understanding these deter-
minants is crucial for the success of possible interventions. Finally, we emphasize the overarching impor-
tance of a sociocultural approach to preventing antibiotic resistance in the community.
he epidemiology of antibiotic-resistant Streptococcus
pneumoniae varies tremendously between different coun-
tries and continents (1). In Europe, high rates of penicillin-
resistant pneumococci have been recorded in France and
Spain, whereas countries like Germany and Switzerland are
only marginally affected (2,3). The reasons for the uneven
geographic distribution of antibiotic-resistant pneumococci are
not fully understood. 
In this article, we focus on a comparison of pneumococcal
resistance rates between Germany and France, two neighbor-
ing European countries with well-developed health-care sys-
tems accessible for virtually the entire population. Moreover,
living standards, expenditures on health, and key survival sta-
tistics (infant deaths, life expectancy) are roughly equivalent,
which allowed us to assume that at least in terms of general
health indicators both countries could be judged to be compa-
rable (4). We reviewed recent epidemiologic data about antibi-
otic resistance in clinically relevant pneumococcal isolates of
patients in Germany and France and explored different
hypotheses to explain the observed differences between the
two countries. The main questions addressed are: 1) Do impor-
tant differences exist in antibiotic-prescribing practices in the
outpatient setting? 2) Do the factors influencing decisions on
antibiotic use differ? 3) Are these differences related to socio-
cultural and other macro-level determinants? In particular, we
sought to offer potential methods for future international com-
parisons designed to aid in developing effective strategies for
decreasing the spread of antibiotic-resistant microorganisms in
the community.
Methods
A computer-based literature review was undertaken with the
MEDLINE database from 1980 to the present. While references
were sought by using specific subject headings related to differ-
ences in the prevalence of antibiotic-resistant pneumococci
between Germany and France and reasons for the observed dis-
parity (e.g., antibiotic use and prescribing), the paucity of rele-
vant retrievals prompted us to repeat the search by using
keywords specific for each of the questions asked. This
extended search included articles about differences in economic
and sociocultural determinants (e.g., perception of illness, soci-
etal background of pharmaceutical consumption). Additional
references were identified from the references cited in these
reports and personal files. Papers in English, German, and
French were reviewed. Antibiotic use on a national level was
expressed as defined daily doses (DDD) of different antibiotic
agents per 1,000 inhabitants per day, one DDD being the stan-
dard daily dose of an antibiotic agent for 1 day’s treatment (5).
Epidemiology of Resistant Pneumococci
Among all clinical isolates of S. pneumoniae collected
from patients of all ages throughout Europe in 1998, 93%
(n=168) were susceptible to penicillin (MIC <0.06 mg/L) in
Germany, whereas only 47% of French isolates (n=167)
remained fully penicillin-susceptible (6). In the same multina-
tional study, 4% and 47% of pneumococcal isolates were
erythromycin-resistant (MIC >1 mg/L) in Germany and
France, respectively. A national surveillance study about the
prevalence of penicillin-resistant S. pneumoniae recovered
from patients with respiratory tract infections in Germany
from 1998 to 1999 showed that of 961 isolates, 93% were fully
susceptible to penicillin G and 6% had intermediate suscepti-
bility (7). Three strains expressed high-level resistance to pen-
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icillin (MIC >2 mg/L) in that study. In contrast, several recent
reports confirm the high prevalence of antibiotic-resistant
pneumococci in France (2,3,8–10). For instance, a national
surveillance study conducted in France in 1999 demonstrated
that the prevalence of penicillin-nonsusceptible (MIC >0.12
mg/L) and erythromycin-resistant pneumococcal isolates
(n=14,178) were 43% and 51%, respectively (10). We found
that the prevalence of antibiotic-resistant pneumococci is
sharply divided between France and Germany. Figure 1 (A and
B) summarizes currently available aggregate data on the prev-
alence of penicillin- and erythromycin-resistant pneumococci
in clinical isolates from both countries (3,6,7,9–11).
Explanatory Dimensions
To explain the differences in pneumococcal resistance
rates, we identified several dimensions that influence decisions
on antibiotic use. These dimensions are derived from the con-
cept that outpatient antibiotic use not only depends on clinical
and microbiologic considerations and the frequency of respira-
tory tract infections but is also related to sociocultural and eco-
nomic factors (12–14). More precisely, the first dimension of
our proposed framework (Figure 2) concerns the prescribers of
antibiotics, physicians, who may differ in their use, dosing,
and choice of antibiotic agents. The second dimension con-
cerns patient demand and health-belief differences. A third
group of determinants of antibiotic consumption is linked to
macro-level factors influencing the prescription of antibiotics,
such as sociocultural factors (e.g., child-care practices) and
regulatory health-care policies. This article has been structured
along these explanatory dimensions. Finally, we discuss com-
peting explanations and implications of the presented data.
Volume of Outpatient Antibiotic Use
The association between community use of antibiotics and
antibiotic-resistant pneumococci has been amply demonstrated
(15–17). This relationship raises the question of whether dif-
ferences in the volume and pattern of outpatient antibiotic use
exist between Germany and France.
Analyses of national sales data from Germany and France
are summarized in Figure 3 (18,19). These data show that,
from 1985 to 1997, retail sales of oral antibiotics in France
were almost three times higher than sales in Germany. For
instance, in 1997, France used 36.5 DDD/1,000 population/
day versus 13.6 DDD/1,000 population/day in Germany (Fig-
ure 3) (19). In addition, Germany had a higher relative use of
narrow-spectrum penicillins, cotrimoxazole, and tetracyclines
and a much lower use of broad-spectrum penicillins, cepha-
losporins, and fluoroquinolones, compared to France (2,19).
Overall, among 18 industrialized countries, Germany had the
third lowest and France had the highest antibiotic utilization
rate in the outpatient setting throughout the 1990s (18,19).
Antibiotic-Prescribing Practices 
for Respiratory Tract Infections
Antibiotic-prescribing practices for respiratory tract infec-
tions vary tremendously between France and Germany. Anti-
biotic prescription rates in France and Germany for common
cold and tonsillopharyngitis were 48.7 and 94.6 versus 7.7
and 69.6 per 100 outpatient consultations, respectively
(Table) (12). A French survey showed that, during a 3-month
period in 1991, 25% of the French population was treated
with an antibiotic, compared with 17% in 1980 (22). In partic-
ular, the frequency of respiratory tract infections with a pre-
sumed viral cause that were diagnosed and treated with
antibiotics increased by 86% for adults and by 115% for chil-
dren in the 11-year period (22).
A pan-European survey showed marked differences in the
rate of nonprescription of antibiotics at the first consultation for
respiratory tract infections (Table) (20). In Germany, the
absence of antibiotic prescription reached 41%, even in a case
of a suspected pneumonia (21). This lower rate of prescriptions
can be explained by a higher recourse to diagnostic investiga-
tions and a watchful waiting approach in Germany (21). In fact,
in 43% of all suspected cases of respiratory tract infection in
Germany, diagnostic tests were performed, compared to 21% in
Figure 1. Summary of published aggregate data on the prevalence of
pneumococci with intermediate (MIC >0.12 mg/L) and high-level (MIC
>2.0 mg/L) resistance (A), and the prevalence of erythromycin-resistant
pneumococci (B), France and Germany (3,6,7,9–11).PERSPECTIVE
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France (Table). Another recently published study (23) con-
firmed that lower respiratory tract infections seen by general
practitioners in France led to few requests for supplementary
investigations. Thus, to decrease diagnostic uncertainty and
inappropriate prescribing for acute bronchitis and mild exacer-
bation of chronic bronchitis in France, more precise diagnostic
criteria and cost-effective tests are needed.
A study by Guillemot et al. (24) also demonstrated that fre-
quent low-level prescribing of penicillin selects for resistant
strains of S. pneumoniae in the oropharyngeal flora. When
finally prescribed, penicillin agents are usually given in higher
doses to German patients than French patients. In a European
study, 30% of German adult patients received >3g per day of
amoxicillin for lower respiratory tract infections, whereas
French patients received considerably lower antibiotic dosages
(21). In another survey from France, a high percentage of anti-
biotic prescriptions were underdosed as compared to clinical
recommendations, particularly in children (25). Moreover,
some authorities have linked the high prevalence of penicillin-
nonsusceptible pneumococci in France to widespread replace-
ment of amino-penicillins by oral cephalosporins, many of
which achieve a T > MIC (time for which non–protein-bound
concentrations exceed the MIC) of <40% for S. pneumoniae,
resulting in inadequate killing of bacteria (26). In contrast, the
prescription of high-dose amino-penicillins in Germany may
be an additional factor contributing to the lower prevalence of
penicillin-resistant pneumococci in that country (27).
The Cultural Perspective
Cultural factors determine which signs and symptoms are
perceived as abnormal and thus require medical care and phar-
maceutical treatment. Illness perception influences help-seek-
ing behavior and clinical outcome (28). In particular, cultural
views of infectious conditions that require antibiotic treatment
differ between countries (14).
Many French people seeking medical care because of
cough and sputum production request to be treated by antibiot-
ics; by contrast, most Germans consider such treatment as
unnecessary overmedication (Table) (12,29). In Germany,
many patients accept individualized, complementary medicine
and its most refined form, homeopathy, as an equivalent
approach for the treatment of respiratory diseases, since great
attention is given to improving the body’s natural defense
(30,31). A survey commissioned by the European Union
among 1,577 opinion leaders in the health-care sector showed
that alternative medicines such as homeopathy were supported
by 42% of survey participants in Germany versus 23% in
France (32). A recently published survey among 2,111 Ger-
mans >16 years of age showed that 83% had some sympathy
for complementary medicine, whereas 40% disliked antibiot-
ics because they could undermine natural immunity (33).
Another opinion poll among 2,647 Germans indicated that the
prevalence of using alternative medicine in Germany was the
highest among all industrialized countries: 65% in 1996; in
1970, the corresponding figure was 52% (34). Most partici-
pants (84%) seemed motivated to use alternative methods
largely because of strong misgivings about the potential
adverse effects of pharmacotherapy (34).
Based on these health-belief factors, most German physi-
cians follow a less aggressive, watchful-waiting approach in
the case of non–life-threatening infections. In particular, Ger-
man physicians agree that antibiotics are not first-line drugs
for the treatment of uncomplicated respiratory tract infections.
Indicative of the general attitude is this statement by a German
general practitioner: “We never give antibiotics for a common
cold ….On the first visit we would only give aspirin. After five
days we would do a blood sedimentation and listen to the
lungs. Then we might give antibiotics” (35).
In France, physicians have repeatedly reported that unreal-
istic patient expectations, patient pressure to prescribe antibi-
otics, and insufficient time to educate patients about the
inefficacy of antibiotics for upper respiratory tract infections
are the major reasons why antibiotics are prescribed for these
self-limiting diseases (12,29,36,37). In a Pan-European survey
(36), the demand index for antibiotics among patients in
France was 2.2, surpassed only by Turkey (2.4). In that survey,
France was the only European country where >50% of the
interviewees definitely expected an antibiotic for the treatment
of “flu.” Most notably, 82% of French mothers expected anti-
biotics for their child’s earache (36). In another recently pub-
lished survey, French parents agreed more strongly than
physicians that “all ear infections should be treated with anti-
biotics” (38).
Figure 2. Framework of nonmicrobiologic factors influencing outpatient
antibiotic use and prevalence of pneumococcal resistance.
Figure 3. Outpatient antibiotic utilization (18,19), France and Germany,
1985–1997. DDD, daily defined doses.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1463
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However, French physicians may overestimate the extent
to which patient satisfaction depends only on receiving an
antibiotic prescription; therefore practitioners should be con-
vinced that the primary determinant of patient satisfaction is
not prescribing antibiotics but rather, effective communication
about the patient’s illness (39). For instance, in a recently pub-
lished study from Nottingham, United Kingdom, antibiotic use
for acute bronchitis was reduced by 25% in those patients who
received information and reassurance about the benign nature
of their disease (40).
The Social Perspective
Social factors also influence antibiotic use and resistance
rates in France and Germany. This influence can be best illus-
trated by otitis media, the leading reason for excessive antimi-
crobial use in French children (20). Attendance at a child-care
center outside the home correlates strongly with an increased
risk of otitis media and acquisition of drug-resistant pneumo-
cocci (16,41). Therefore, the great differences in the availabil-
ity and usage of nonparental day-care facilities between
France and Germany are not unexpected.
In France, a long tradition of early childhood education
exists in the public sector. Known as “écoles maternelles,”
nearly 100% of 3- to 5-year-olds attend these publicly funded
pre-schools; about 35% of 2-year-olds also attend (42). In con-
trast, <10% of German infants in this age group were in the
care of an external child-care provider (43). In 1998, 340 nurs-
ery places per 100,000 population were available in France,
compared to 200 places per 100,000 population in Germany
(43). Thus, many more French infants are in the care of an
external child-care provider. If they enter child-care, German
children enter it later than French children; this practice delays
the peak incidence and the cumulative burden of otitis media
and associated antibiotic use (44).
Because of the transmission of antibiotic-resistant pneu-
mococci among infants in nurseries in France, a panel of
national experts recommended encouraging alternatives that
could delay placement in day-care centers until children are 18
months old (45). However, this recommendation seems diffi-
cult to follow, since attendance at a child-care center outside
the home is a necessity for many families. In fact, France has a
high proportion of women employed outside the home: in
1990, 72% of the women ages 25 to 54 years were employed
in France compared to 60% in Germany (46). Moreover, <40%
of single mothers in Germany are employed, compared to 82%
in France (47). Since out-of-home child-care practices are
unlikely to change and the proportion of two-career families
will likely not decrease in France, promoting smaller child-
care size, grouping children in small sub-units, and providing
pneumococcal vaccinations could possibly reduce the risk of
pneumococcal cross-infection (48–50).
By contrast with Germany, another important risk factor
for otitis media and pneumococcal infection in infants (50) is
highly prevalent in France: the absence of breast-feeding
beyond the first weeks of life. Breast-feeding practices vary
considerably throughout Europe (51). A national survey con-
ducted in 1995 among 12,179 babies at French maternity hos-
pitals showed that France had the lowest level among Western
countries for which national data on breast-feeding were avail-
able: only 52% of newborns were breastfed at hospital dis-
charge, including 10% of babies partially breastfed (52).
Efforts to encourage breast-feeding are needed in France to
promote infant health and decrease susceptibility to respiratory
tract infections.
Differences in Regulatory Practices
Antibiotic prescriptions are affected through reimburse-
ment policies and the structure of the pharmaceutical market.
Table. Comparison of patterns of antibiotic prescribing and diagnostic tests for respiratory tract infections, France and Germanya
Variables France Germany
Average no. office visits for acute tonsillopharyngitis per 1,000 population 136 51
Average no. antibiotic prescriptions per 100 office visits for acute tonsillopharyngitis  94.6 69.6
Average no. office visits for common cold per 1,000 population 253 19
Average no. antibiotic prescriptions per 100 office visits for common cold  48.7 7.7
% of patients not receiving antibiotics at first office visit for 
Suspected community-acquired pneumonia 82 3
Acute bronchitis 73 1
Exacerbation of chronic bronchitis 52 6
Viral lower respiratory tract infection 20 41
% of cases of suspected lower respiratory tract infection with diagnostic tests performed
Chest radiograph 18 27
Peripheral blood leukocyte count 14 27
Microbiologic sputum examination 31 2
aSources: (12,20,21). PERSPECTIVE
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The average level of retail prices for pharmaceutical products
is very low in France. For example, if the price in France is
100, the level would be 162 in the United Kingdom and 175 in
Germany (53). Another study (54) demonstrated that Laspey-
res (U.S. quantity-weighted) indexes for prices per drug dose
show large differences compared to the reference country
(USA): Germany, +24.7%; Canada, +2.1%; Japan, –12%;
Italy, –13%; United Kingdom, –17%; and France, –32%.
Because of this low level of pharmaceutical pricing, France
not only is ranked first in the consumption per capita of outpa-
tient antibiotics but also had the 3rd highest consumption of
pharmaceutical products per capita among all countries in the
Organization for Economic Cooperation and Development in
1997 (55). The overall per-capita expenditures on pharmaceu-
ticals in 1997, adjusted for cost-of-living differences, were
$352 in France versus $294 in Germany (56).
Historically, the French drug economy has largely been
regulated by product price control and has been structured as a
low-price, high-quantity system, whereas Germany has tended
more towards a high-price, low-quantity system (53,57). The
different systems of price regulation are responsible to some
extent for three important features that influence antibiotic
prescribing patterns. First, generic medicines have played only
a minor role (<5%) in the French pharmaceutical market
(58,59), but they account for 39% of all prescribed medicines
in volume and 38% in value in Germany (59). This feature
contributes to the observed trend in France of using newer
antibiotics; in Germany, by contrast, narrow-spectrum, generic
agents are more commonly used (19). A second factor is that
until recently, French pharmacies were better remunerated if
they dispensed large volumes of relatively expensive drugs
such as oral broad-spectrum cephalosporins (59). By contrast,
pharmacy remuneration in Germany is calculated by applying
regressive percentages to different price bands: the lower the
price, the higher the pharmacist’s share (60). Finally, the
French pricing system has induced companies to develop
aggressive promotional efforts and marketing campaigns to
curb sales and compensate for low prices (53). Consequently,
we speculate that French and German general practitioners are
exposed to very different marketing information on antibiotics
(12,29). However, representative data for both countries are
not publicly available on that issue.
Most importantly, health authorities in Germany have
more regulatory power by allocating collective expenditure
caps and, therefore, have a broader impact on drug use than
that exerted by similar agencies in France. In 1993, the intro-
duction of capped physician budgets and a system of reference
pricing in Germany led to a switch in prescribing preferences
and an incentive for German physicians to avoid expensive
products priced above the reference price, such as oral broad-
spectrum cephalosporins (54). Consequently, from 1994 to
1997, the volume of antibiotics prescribed decreased tempo-
rarily from 334 million to 305 million DDDs (57).
In France, the introduction of national prescription guide-
lines (Références Médicales Opposables) for upper respiratory
tract infections in 1994 did not decrease the overall volume of
outpatient antibiotic use and had only a modest economic
impact. However, prescription patterns have changed in line
with those guidelines and led to a decrease in the use of fluoro-
quinolones and oral cephalosporins and to a substantial increase
in macrolide use for acute bronchitis and pharyngitis (61).
Possible Alternative Explanations
Several alternative explanations for the observed differ-
ences in antibiotic resistance rates can be made. First, variation
in antibiotic use may be caused by differences in the frequency
of respiratory tract infections. However, the rate of antibiotic
consumption in France implies a rate of bacterial respiratory
illness that is at least 5 times higher than the reported rates in
the literature (20); therefore, the high antibiotic usage cannot
be justified by known rates of the principal bacterial infections
of the respiratory tract encountered in the community. As
stated by Guillemot et al. (22), the observed increase in respi-
ratory tract infections with a presumed viral cause cannot be
explained by demographic evolution, age distribution, or by
the occurrence of large epidemics in France. Second, clonal
differences may be responsible for the observed differences.
However, we did not identify any study suggesting that the cir-
culating strains and serotypes of antibiotic-resistant pneumo-
cocci in France are intrinsically more virulent or transmissible
compared to strains circulating in Germany (62,63). Third,
another possible reason for the epidemiologic gap between
both countries might be differences in diagnostic practice. For
instance, two recent studies suggest underdiagnosis of invasive
pneumococcal disease in Germany (64,65). However, we have
no reason to believe that France has a significantly higher
detection and identification rate of pneumococcal infection,
when considering the previously mentioned diagnostic prac-
tices in France (22,23). Finally, although obtaining comparable
data about the severity of illness of outpatients in France and
Germany is difficult, no evidence shows that the French
health-care system is more likely to treat patients who are
more severely ill or who have a higher likelihood of severe
infection (66). Nevertheless, the heterogeneity of patient popu-
lations and their varying susceptibility to infection should be
better described in future studies about international differ-
ences in antibiotic use and resistance rates.
Conclusions
This report represents a unique attempt to combine differ-
ent data sources to give a more complete picture of sociocul-
tural and economic forces influencing the ecology of antibiotic
use and pneumococcal resistance in two large European coun-
tries. The published literature regarding the prevalence of anti-
biotic-resistant pneumococci provides convincing evidence
that France and Germany have sharply different rate. The rea-
sons for the observed resistance gap are multifactorial and
include substantial differences in physicians’ and patients’
attitudes towards antibiotics; sociocultural and economic fac-
tors; and disparities in regulatory practices. Studies areEmerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1465
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remarkably consistent in documenting the high frequency with
which antibiotics are used in France for upper respiratory tract
infections without appropriate microbiologic rationale. Unfor-
tunately, despite the widespread publication of recommenda-
tions over the last decade and some modest modifications in
the pattern of antibiotic utilization (61), the willingness of
French general practitioners to change their antibiotic-pre-
scribing habits has been at best grudging and at worst nonex-
istent (29,67). As shown in a recently published survey from
the United States (68), little evidence suggests that national
guidelines alone, particularly when they emphasize societal
concerns, have much impact on individual antibiotic-prescrib-
ing behavior. Therefore, much more attention needs to be
focused on patient expectations and perceptions of illness and
the constraints of medical practice (39). Major improvements
are needed in communicating to individual patients (69) and in
informing the general public about the risks of inappropriate
antibiotic use (13,70). In November 2001, the former French
Minister of Health, Dr. Bernard Kouchner, took an important
step in this direction by allocating 30 million euros for public
awareness campaigns about antibiotic misuse and resistance
(71). In this respect, France may also learn from the experi-
ence of countries like the United States, Canada, Belgium, and
Sweden, which all managed to reduce excessive antibiotic use
on a national level (19,72–74). In particular, a number of Scan-
dinavian studies have suggested that national antibiotic poli-
cies together with public information campaigns and changes
in reimbursement policies can be effective (55,75).
In Germany, low prevalence of pneumococcal resistance
coincides with less antibiotic consumption, selection of nar-
row-spectrum antibiotics, higher dosing of amino-penicillins,
and possibly, better treatment compliance (2). Thus, learning
from Germany’s experience with regard to the low prevalence
of penicillin-resistant pneumococci may have some value for
other countries. However, German health authorities should be
careful in regard to the increasing spread of antibiotic-resistant
pneumococci (11,76). A rational approach to the control of
antibiotic-resistant pneumococci and the surveillance of anti-
biotic use in the outpatient setting are urgently warranted in
Germany to preserve the still favorable situation.
An interesting question remains about whether differences
in national antibiotic-prescribing patterns affect the rates of ill-
ness and death from complications of respiratory tract infec-
tions. A recent study (77) showed, for instance, that the
Netherlands, a country with low antibiotic prescription rates
for acute otitis media, had an incidence rate of acute mastoidi-
tis of 3.8/100,000 person-years, whereas in countries with very
high prescription rates, incidence rates were considerably
lower, ranging from 1.2 to 2.0/100,000 person-years. A con-
servative approach and withholding of antibiotics in the treat-
ment of acute otitis media may also have increased the
occurrence of acute mastoiditis in Germany (78). A recently
published article (79) indirectly suggests that the low rates of
Haemophilus influenzae type B meningitis in some countries,
particularly in Asia, may be due at least partially to extensive
antibiotic use. However, no recently published, representative
surveillance data exist about illness and death from complica-
tions of common respiratory tract infectious in France or Ger-
many. Future international studies about the use of outpatient
antibiotics (80) should include cross-country surveillance data
for serious infectious complications such as mastoiditis, acute
rheumatic fever, meningitis, or suppurative complications of
pharyngitis (81).
Finally, we argue that effects exerted at the macro-level by
the cultural and socioeconomic environment contribute sub-
stantially to the observed differences in prescribing practices
and related antibiotic resistance rates. Consequently, failure to
understand the sociocultural and economic perspectives of
antibiotic consumption and resistance will lead to inadequate
conclusions about the chances of success for possible interven-
tions. More research to inform decision-makers on the deter-
minants of the variation in antibiotic use and resistance
patterns is urgently needed.
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